SRPT Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
381.4M
-5.0%
401.3M
-45.1%
730.8M
+65.0%
442.9M
+10.9%
399.4M
Cost of Revenue
188.5M
+26.2%
149.4M
+37.3%
108.8M
-72.7%
398.7M
+164.4%
150.8M
Gross Profit
192.8M
-23.4%
251.9M
-59.5%
622.0M
+1306.5%
44.2M
-82.2%
248.6M
Operating Expenses
201.9M
-15.4%
238.6M
-9.5%
263.6M
-42.2%
455.8M
+29.5%
352.0M
R&D
82.5M
-9.5%
91.3M
-40.7%
154.0M
-52.7%
325.3M
+48.6%
218.9M
SG&A
118.6M
+10.2%
107.6M
-1.2%
109.0M
-15.1%
128.3M
+39.6%
91.9M
Operating Income
-9040000
-168.0%
13.3M
-96.3%
358.4M
+187.1%
-411583000
-298.1%
-103389000
EBITDA
-3140000
-105.0%
62.7M
-83.0%
369.0M
+191.2%
-404831000
-811.2%
-44429000
Net Income
-28461000
-482.0%
-4890000
-101.5%
331.0M
+217.0%
-282847000
-459.3%
-50568000
EPS (Basic)
$-0.27
-440.0%
$-0.05
-101.6%
$3.15
+216.7%
$-2.70
-440.0%
$-0.50
EPS (Diluted)
$-0.27
-440.0%
$-0.05
-101.7%
$2.88
+198.0%
$-2.94
-488.0%
$-0.50
Shares (Diluted)
105.9M
+0.5%
105.4M
-13.5%
121.9M
+26.7%
96.3M
-4.0%
100.2M
Sarepta Therapeutics, (SRPT) — Financials